Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Methods are provided for delivering oligonucleotide compounds into osteoclasts or osteoclast precursor cells. The compounds according to one embodiment are targeted to a nucleic acid encoding RANK and are capable of modulating the expression of RANK. Also provided are methods for modulating osteoclast differentiation by delivering such compounds into osteoclast precursor cells. Cellular delivery of the oligonucleotide compounds may be carried out by transfecting the compounds into osteoclasts or osteoclast precursor cells in the presence of a non-liposomal transfection agent. Examples of suitable non-liposomal transfection agents include FuGENE 6 and Effectene®. The disclosed methods may be advantageously applied in the discovery of diagnostics and therapeutics for bone diseases associated with osteoclast activity.

Abstract: The present invention describes a newly discovered ubiquitin conjugating enzyme homologue, called RATL1d6 herein, and its encoding polynucleotide, isolated and identified from activated T lymphocytes. Also described are expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies associated with the activity and use of the newly-discovered polynucleotide and/or polypeptide of the present invention. Methods for treating, diagnosing, preventing and screening for disorders related to the expression of the RATL1d6 ubiquitin conjugating enzyme polypeptide are described.

Abstract: The invention provides novel human polynucleotides unique to, associated with, or highly expressed activated T-lymphocytes (Regulated in Activated T Lymphocytes). The novel polynucleotides were derived from a cDNA subtraction library constructed from human peripheral blood T lymphocytes activated with antibodies against CD3 and CD28 cell surface antigens. The invention also provides for the use and production of the polynucleotides, antisense polynucleotides, amino acid sequences, and/or polypeptides, peptides, and antigenic epitopes thereof encoded by these polynucleotides, and to compositions and methods comprising the polynucleotides and polypeptides and peptides identified herein for modulation of an immune response and for the diagnosis, prevention, or treatment of disorders associated with aberrant cellular development and differentiation including cancer and inflammation, graft vs. host disease, transplantation rejection and autoimmune disease.

Abstract: The present invention describes a newly discovered polynucleotide encoding a protein involved in the cell signaling cascade, called RET16, cloned, isolated and identified from TNF-alpha stimulated human microvascular endothelial cells, as well as mouse and rat RET16 orthologs thereof. Also described are the RET16 polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Methods for screening for modulators, particularly inhibitors, of the human RET16 protein, and use of the RET16 polynucleotide and polypeptide for therapeutics and diagnostics are described.